Daily bars for up to one year, weekly bars for the 5-year view. Averages are 50/200 trading days (10/40 weeks on the 5-year view).
Novo-Nordisk A/S (NVO) is trading at $38.33, up 0.41% on the day. Its market value of $171.13B makes it the 90th largest of the 300 companies we follow.
Over the past 52 weeks it has traded between $34.20 and $61.21, so it sits 37.4% below the top of that range. Holders are behind 31.6% over twelve months, and down 18.1% across the last three months.
On the chart it has slipped under both the 50-day ($46.02) and 200-day ($44.90) moving averages; RSI is 29, which some call oversold, and the last 30 sessions moved at roughly 38% annualized volatility.
In the quarter ended Jun 2026 the company brought in DKK 78.49B of revenue, up 2.1% from a year earlier, with DKK 20.99B of net profit (a 35.3% margin).
The stock changes hands at 9.6 times trailing earnings, 69% below its five-year average of 31.2.
4 analysts follow the stock and the average call is "hold". The mean target, $43.67, sits 13.9% over where the stock trades.
This summary is put together from the numbers on the page and updates when they do. It describes the data; it is not a forecast or a recommendation.
Novo Nordisk is a Danish drugmaker best known for the diabetes and obesity drugs Ozempic and Wegovy.
What tends to move it. Competition from Eli Lilly, pricing pressure on GLP-1 drugs and its next-generation candidates drive the stock.
Written by hand by the BeStock desk and revised when a business changes. See how we work. Spot something out of date? Tell us.
Price return over each window, from adjusted daily and weekly closes
| Indicator | Value | Signal |
|---|---|---|
| Price vs 20-day average | -12.8% | Bearish |
| Price vs 50-day average | -16.7% | Bearish |
| Price vs 200-day average | -14.6% | Bearish |
| 50-day vs 200-day | 50d above 200d | Bullish |
| RSI (14) | 28.9 | Neutral |
| MACD (12,26,9) | -1.71 | Bearish |
| Bollinger band position | -5% | Neutral |
Standard indicator readings worked out from daily closes. They describe how the price has behaved, not where it is going.
Quote as of Sep 24, 2026 2:00 pm ET. Prices can lag the live tape. This is background information, not a recommendation.
Ranks are among the 300 or so U.S.-listed stocks BeStock covers, recalculated whenever prices refresh. A row is left out when the measure does not apply, such as yield for a stock that pays no dividend.
Latest reported quarter: Q2, ended Jun 2026 · reported in DKK
Quarter 2026/Q2
"Implied move" is the size of move the options market was pricing ahead of the report. Move is the stock’s change on the first session after the release.
Multiples measured against the stock's own five-year history
Near the bottom of its 5-year range · 4th percentile, 5-year average 31.2x
#577 of 2978 stocks by PE (1 = cheapest)
Near the bottom of its 5-year range · 2nd percentile, 5-year average 23.2x
#4398 of 5303 stocks by PB (1 = cheapest)
Near the bottom of its 5-year range · 4th percentile, 5-year average 10.7x
#3429 of 5143 stocks by PS (1 = cheapest)
Dashed line is the 5-year average; the shaded band is one standard deviation either side.
Who holds it, who is betting against it, and where the big money is moving
Net of large-order buying minus selling, in USD. Over this window: +$1.95M (9 inflow days, 11 outflow days).
Across the full calendar years shown, the annual payout grew by roughly 4.5% a year.
$38.33 is the latest print for NVO, a move of +0.41% against yesterday's close of $38.17. Today's low and high so far: $37.92 and $38.72.
Equity value comes to $171.13B at the current price. By that measure it is number 90 of the 300 names in our coverage.
Buyers pay 9.6 times the last twelve months of profit (EPS $3.51). Averaged over five years the multiple has been 31.2, and today's level ranks in the 4th percentile of its own history.
The year's floor is $34.20 and the ceiling $61.21. Shares are 37.4% away from that ceiling.
It does. Payouts over the past twelve months work out to a 4.65% yield; the latest ex-dividend date was August 17, 2026.
Of 4 analysts, 0% say buy, 75% hold and 25% sell. Price targets average $43.67, with the most cautious at $40.00 and the most optimistic at $47.00.
Novo Nordisk is a Danish drugmaker best known for the diabetes and obesity drugs Ozempic and Wegovy.
BeStock publishes market data and analysis for information only. Nothing here is investment advice or a solicitation to buy or sell any security. Quotes may be delayed and figures can contain errors; check primary sources before you trade. How we source and calculate these pages.